Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells

Carcinogenesis

Volumn 31, Issue 2, 2010, Pages 192-200

  Behera, Reeti ^a   Kumar, Vinit ^a   Lohite, Kirti ^b   Karnik, Swapnil ^b   Kundu, Gopal C ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b Grant Medical Foundation   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; DNA; JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; OSTEOPONTIN; PROTEIN BCL 2; STAT3 PROTEIN; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARCINOGENICITY; CELL MIGRATION; CONTROLLED STUDY; DNA BINDING; ENZYME PHOSPHORYLATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; NONOBESE DIABETIC MOUSE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SCID MOUSE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; APOPTOSIS; BREAST TUMOR; CELL ADHESION; CELL MOTION; CELL NUCLEUS; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHAVBETA3; JANUS KINASE 2; MICE; MICE, INBRED NOD; MICE, SCID; OSTEOPONTIN; PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77649207043     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp289     Document Type: Article

References (45)

1. Steller, H. (1995) Mechanisms and genes of cellular suicide. Science, 267, 1445-1449.
2. Lai, Z.C. et al. (2005) Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell, 120, 675-685.
3. Rahaman, S.O. et al. (2002) Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene, 21, 8404-8413.
4. Bowman, T. et al. (2000) STATs in oncogenesis. Oncogene, 19, 2474-2488.
5. Song, H. et al. (2005) A low-molecular-weight compound discovered through virtual database screening inhibits STAT3 function in breast cancer cells. Proc. Natl Acad. Sci. USA, 102, 4700-4705.
6. Bromberg, J.F. et al. (1999) Stat3 as an oncogene. Cell, 98, 295-303.
7. Bromberg, J. et al. (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene, 19, 2468-2473.
8. Colomiere, M. et al. (2009) Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br. J. Cancer, 100, 134-144.
9. Bellahcéne, A. et al. (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat. Rev. Cancer, 8, 212-226.
10. Sodek, J. et al. (2000) Osteopontin. Crit. Rev. Oral Biol. Med., 11, 279-303.
11. Rangaswami, H. et al. (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol., 16, 79-87.
12. Philip, S. et al. (2001) Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem., 276, 44926-44935.
13. Samanna, V. et al. (2006) Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp. Cell Res., 312, 2214-2230.
14. Rangaswami, H. et al. (2004) Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem., 279, 38921-38935.
15. Jain, S. et al. (2006) The crucial role of cyclooxygenase-2 in osteopontininduced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res., 66, 6638-6648.
16. Chakraborty, G. et al. (2008) Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res., 68, 152-161.
17. Chakraborty, G. et al. (2006) The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr. Mol. Med., 6, 819-830.
18. Wang, X. et al. (2008) Increased expression of osteopontin in patients with triple-negative breast cancer. Eur. J. Clin. Invest., 38, 438-446.
19. Rodrigues, L.R. et al. (2007) The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol. Biomarkers Prev., 16, 1087-1097.
20. Pan, H.W. et al. (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 98, 119-127.
21. Shevde, L.A. et al. (2006) Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin. Exp. Metastasis, 23, 123-133.
22. Furuya, F. et al. (2007) Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling. Mol. Cell. Biol., 27, 6116-6126.
23. Philip, S. et al. (2003) Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J. Biol. Chem., 278, 14487-14497.
24. Kida, H. et al. (2008) GP130-STAT3 regulates epithelial cell migration and is required for repair of the bronchiolar epithelium. Am. J. Pathol., 172, 1542-1554.
25. Ni, C.W. et al. (2004) Interleukin-6-induced JAK2/STAT3 signaling pathway in endothelial cells is suppressed by hemodynamic flow. Am. J. Physiol. Cell Physiol., 287, C771-C780.
26. Rosen, D.G. et al. (2006) The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer, 107, 2730-2740.
27. Abdulghani, J. et al. (2008) Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol., 172, 1717-1728.
28. Wang, L. et al. (2009) E-cadherin decreased human breast cancer cells sensitivity to staurosporine by up-regulating Bcl-2 expression. Arch. Biochem. Biophys., 481, 116-122.
29. Leslie, K. et al. (2006) Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res., 66, 2544-2552.
30. Bhattacharya, S. et al. (2005) STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem. J., 392, 335-344.
31. Darnell, J.E. (2005) Validating Stat3 in cancer therapy. Nat. Med., 11, 595-596.
32. Rahaman, S.O. et al. (2005) Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Rα2. Cancer Res., 65, 2956-2963.
33. Xie, T.X. et al. (2006) Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res., 66, 3188-3196.
34. Alvarez, J.V. et al. (2006) Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res., 66, 3162-3168.
35. Leeman, R.J. et al. (2006) STAT3 as a therapeutic target in head and neck cancer. Expert Opin. Biol. Ther., 6, 231-241.
36. Diaz, N. et al. (2006) Activation of Stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated Src and survivin expression. Clin. Cancer Res., 12, 20-28.
37. Chen, C.L. et al. (2007) Stat3 activation in human endometrial and cervical cancers. Br. J. Cancer, 96, 591-599.
38. Ni, Z. et al. (2000) Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res., 60, 1225-1228.
39. Levy, D.E. et al. (2006) STAT3: a multifaceted oncogene. Proc. Natl Acad. Sci. USA, 103, 9964-9969.
40. Alvarez, J.V. et al. (2005) Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res., 65, 5054-5062.
41. Jain, S. et al. (2008) Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res., 68, 7750-7759.
42. Zhao, S. et al. (2008) Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res., 68, 4221-4228.
43. Shain, K.H. et al. (2009) Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res., 69, 1009-1015.
44. Bernard, B. et al. (2001) Staurosporine-induced apoptosis of HPV positive and negative human cervical cancer cells from different points in the cell cycle. Cell Death Differ., 8, 234-244.
45. Xiong, H. et al. (2008) Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia, 10, 287-297.